EichorEICHOR
Condition: Ted Synced from ClinicalTrials.gov · August 02, 2026

Recruiting studies: Ted

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Clinical Study of Cizutamig in Thyroid Eye Disease
Phase 1 · 1 location(s) · Candid Therapeutics · NCT07597200A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Phase 1/Phase 2 · 44 location(s) · Amgen · NCT06401044Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT07547930Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor
Phase N/A · 3 location(s) · University Health Network, Toronto · NCT07447908Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT07262476Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Phase 2/Phase 3 · 2 location(s) · Sling Therapeutics, Inc. · NCT06112340A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
Phase 3 · 27 location(s) · Zai Lab (Shanghai) Co., Ltd. · NCT07211776Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the A
Phase 4 · 1 location(s) · Shanghai Changzheng Hospital · NCT07152366Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease
NA · 1 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07400757MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
Phase 3 · 1 location(s) · Minghui Pharmaceutical (Hangzhou) Ltd · NCT07257185A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Phase 1 · 1 location(s) · Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06569758Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE Nati
Phase N/A · 1 location(s) · Shanghai Changzheng Hospital · NCT07716397The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO
Phase 4 · 2 location(s) · Shanghai Changzheng Hospital · NCT07152340Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Phase 4 · 1 location(s) · Shanghai Changzheng Hospital · NCT07152392A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopa
Phase 4 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06927375
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.